Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy - 1

NCT ID: NCT00067158

Last Updated: 2017-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

585 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-04-30

Study Completion Date

2004-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to look at how feasible it is to incorporate a state-of-the-art smoking cessation treatment program into community substance abuse treatment programs and its impact on substance abuse and cigarette smoking.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tobacco Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nicotine transdermal system

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is alcohol or drug dependent, in Outpatient Drug-Free or Opiate Substitute program and is interested in quitting smoking

Exclusion Criteria

* Patient is psychotic
* Use of smokeless tobacco
* Use of other smoking cessasation product
* Pregnancy
* Patient has hyper-tension, heart problems, or skin condition
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

New York University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

New York University

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Malcolm Reid, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

New York University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Matrix Institute on Addictions

Los Angeles, California, United States

Site Status

Tarzana Treatment Center

Tarzana, California, United States

Site Status

SPECTRUM

Miami, Florida, United States

Site Status

Center for Drug Free Living

Orlando, Florida, United States

Site Status

Chelsea Arbor Addictions Treatment Center

Ann Arbor, Michigan, United States

Site Status

Psychiatry and Behavioral Medicine Professionals I

Detroit, Michigan, United States

Site Status

Narco Freedom (Bridge Plaza)

Long Island City, New York, United States

Site Status

St. Luke's Roosevelt Hospital Center

New York, New York, United States

Site Status

St. Luke's Roosevelt Hospital Center, Womens

New York, New York, United States

Site Status

Mount Sinai Medical Center

New York, New York, United States

Site Status

Piedmont Behavioral Healthcare

Concord, North Carolina, United States

Site Status

Coastal Horizons Center, Inc.

Wilmington, North Carolina, United States

Site Status

Behavioral Health Services of Pickens County

Pickens, South Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIDA-CTN-0009-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Feasibility of Treatment for Vaping Cessation
NCT04317300 WITHDRAWN EARLY_PHASE1
Treatment to Quit Smoking
NCT00018161 COMPLETED PHASE2
N-acetylcysteine for Tobacco Use Disorder
NCT02737358 COMPLETED PHASE2